Last updated: September 8, 2026
ANTHIM, or obiltoxaximab, is a biodefense monoclonal antibody approved by the FDA for treatment of inhalational anthrax in combination with antibacterial drugs and for post-exposure prophylaxis when alternatives are unavailable or inappropriate. Its commercial market is almost entirely government-driven. The product has limited routine clinical demand, no conventional retail market, and revenue potential tied to U.S. Strategic National Stockpile procurement, replenishment cycles, and public-health preparedness budgets.
The central financial distinction is between contract value and recognized product revenue. The U.S. government awarded Elusys Therapeutics a procurement contract with a ceiling of up to approximately $1.25 billion, but that figure represented potential multi-year purchases and options, not reported sales or guaranteed revenue. Public disclosure does not provide a complete product-level revenue history for ANTHIM.
What is ANTHIM and how does it work?
ANTHIM is the brand name for obiltoxaximab, a recombinant human monoclonal antibody targeting the protective antigen component of Bacillus anthracis toxin.
| Item |
Details |
| Active ingredient |
Obiltoxaximab |
| Brand |
ANTHIM |
| Drug class |
Anthrax antitoxin monoclonal antibody |
| Target |
Bacillus anthracis protective antigen |
| Approved indication |
Treatment of inhalational anthrax with antibacterial drugs; post-exposure prophylaxis when alternatives are unavailable or inappropriate |
| FDA approval |
March 2016 |
| Regulatory pathway |
Animal Rule, supported by animal efficacy studies and human safety data |
| Dosage form |
Intravenous infusion |
| Primary customer |
U.S. government and public-health agencies |
| Principal commercial use |
Strategic National Stockpile preparedness |
The antibody binds protective antigen and blocks the entry of anthrax toxin into susceptible cells. Because inhalational anthrax is rare and treatment is typically concentrated in emergency-response settings, ANTHIM does not operate like a conventional infectious-disease product.
When did ANTHIM receive FDA approval?
The FDA approved ANTHIM on March 18, 2016. The approval covered both treatment and post-exposure prophylaxis for inhalational anthrax. The FDA required use with appropriate antibacterial therapy for treatment because the antibody neutralizes toxin but does not eradicate the underlying bacterial infection.[1]
The product was approved under the FDA’s Animal Rule. This pathway permits approval when human efficacy trials are infeasible or unethical, provided that efficacy is demonstrated in relevant animal models and the product’s safety and pharmacology are characterized in humans.
ANTHIM’s regulatory profile is therefore different from a standard hospital antibiotic:
- Human efficacy data are not based on randomized anthrax treatment trials.
- Commercial demand depends on preparedness procurement rather than disease prevalence.
- Regulatory value comes from emergency-use readiness and stockpile eligibility.
- Manufacturing consistency and shelf life are central economic factors.
How large is the ANTHIM market?
The addressable market is small in routine clinical terms but potentially material in government procurement terms.
There are no recurring commercial treatment volumes comparable with those of antibiotics, vaccines, or immunology biologics. Anthrax cases are rare, and ANTHIM is held primarily for preparedness, emergency response, and post-exposure use. The commercial market is therefore determined by:
- Strategic National Stockpile inventory targets.
- Federal biodefense appropriations.
- Product expiration and replacement requirements.
- Government decisions on product mix between ANTHIM, ANTHRANIL, antibiotics, vaccines, and other countermeasures.
- Manufacturing capacity and delivery schedules.
The product’s annual market opportunity cannot be inferred from anthrax incidence. A single federal order can represent a large share of annual product revenue, while a year without procurement can produce little or no commercial revenue.
What was the BARDA contract value for ANTHIM?
The U.S. Biomedical Advanced Research and Development Authority awarded Elusys a contract valued at up to approximately $1.25 billion for procurement of ANTHIM for the Strategic National Stockpile. The agreement included an initial procurement and additional options over multiple years.[2]
The contract ceiling should not be treated as realized revenue. A procurement contract of this type normally includes:
- Initial guaranteed purchases or funded deliveries.
- Unfunded or contingent option quantities.
- Government termination or modification rights.
- Deliveries spread across several fiscal years.
- Pricing subject to negotiated order terms.
- Potential adjustments based on stockpile requirements and product availability.
Publicly cited initial procurement values were substantially below the total contract ceiling. Reports around the FDA approval and initial stockpiling program described an initial order of roughly 60,000 doses with a value of approximately $44 million.[3]
That initial order implies an average procurement value of about $733 per dose if calculated against the reported figures. This is a rough contract-level average, not a disclosed list price or permanent unit economics measure. Dose requirements vary with patient weight, and government contracts can include packaging, storage, delivery, and other supply obligations.
What is the financial trajectory of ANTHIM?
ANTHIM’s financial trajectory has four distinct phases.
| Phase |
Period |
Financial characteristics |
| Development |
Before 2016 |
Government-supported development, clinical safety work, manufacturing scale-up, and regulatory preparation |
| Initial commercialization |
2016 onward |
FDA approval and initial Strategic National Stockpile procurement |
| Contract fulfillment |
Multi-year period after approval |
Revenue tied to scheduled government deliveries and procurement options |
| Mature stockpile market |
Ongoing |
Replenishment, replacement, shelf-life management, and possible recompetition |
Elusys was a private company, so detailed audited product-level revenue, gross margin, cash flow, and profitability data are not broadly available. The public record supports a conclusion that ANTHIM’s economics were based on government contracting rather than private-market sales.
The company’s financial exposure was shaped by several factors:
- The cost of producing a complex recombinant antibody.
- Batch release and quality-control requirements.
- Low-volume manufacturing.
- Inventory storage and shelf-life management.
- Dependence on one dominant customer.
- Long government procurement cycles.
- The need to maintain readiness even when demand is zero.
- Potential renewal or replacement orders after product expiration.
A large contract ceiling could support company valuation, financing, or acquisition interest, but it did not eliminate execution risk. The financial value of ANTHIM depended on converting options into funded purchase orders and delivering compliant product on schedule.
Who buys ANTHIM?
The U.S. government is the principal economic buyer. The Strategic National Stockpile is the key distribution channel, rather than wholesalers, hospitals, or specialty pharmacies.
Potential end users include:
- Federal emergency-response agencies.
- State and local public-health authorities.
- Military and defense medical systems.
- Hospitals participating in emergency preparedness networks.
- Individuals exposed to confirmed or suspected anthrax in a public-health event.
Routine hospital purchasing is expected to remain limited. The product is not designed for regular prophylactic use in the general population, and its approved indication is tied to inhalational anthrax risk.
The market also has a geopolitical component. Anthrax is a recognized biological threat, and demand can rise when governments increase biodefense spending, revise preparedness standards, or replenish aging inventories.
How does ANTHIM compare with ANTHRASIL?
ANTHIM competes primarily with ANTHRASIL, the brand name for raxibacumab, another monoclonal antibody against Bacillus anthracis protective antigen.
| Attribute |
ANTHIM |
ANTHRASIL |
| Active ingredient |
Obiltoxaximab |
Raxibacumab |
| Product type |
Monoclonal antibody |
Monoclonal antibody |
| Target |
Protective antigen |
Protective antigen |
| FDA status |
Approved |
Approved |
| Primary market |
Government stockpile |
Government stockpile |
| Routine commercial demand |
Very limited |
Very limited |
| Use with antibiotics |
Treatment indication includes antibacterial therapy |
Used with appropriate antibacterial therapy |
| Competitive basis |
Supply reliability, price, stockpile fit, manufacturing capacity |
Supply reliability, price, stockpile fit, manufacturing capacity |
The competition is not primarily based on physician prescribing or sales-force reach. It is based on federal procurement strategy, product availability, contracting terms, manufacturing capacity, shelf life, and portfolio diversification.
Government buyers may prefer to maintain more than one anthrax antitoxin supplier to reduce single-source dependence. That can support ANTHIM’s strategic value even when annual volumes are low.
What is the FDA and regulatory status of ANTHIM?
ANTHIM remains an FDA-approved anthrax antitoxin under the product labeling issued for obiltoxaximab.[1] The FDA-approved use is narrow and tied to inhalational anthrax.
The approval does not create a broad infectious-disease market. It creates a regulated countermeasure position that can be monetized through government procurement and emergency preparedness programs.
Key regulatory considerations include:
- Continued compliance with biologics manufacturing requirements.
- Maintenance of potency and purity specifications.
- Stability data supporting shelf life.
- Appropriate pharmacovigilance and postmarketing obligations.
- Ability to supply product during a public-health emergency.
- Compliance with government contract quality and delivery terms.
What patent and exclusivity protections affect ANTHIM?
ANTHIM’s commercial protection is based on a combination of biologic manufacturing complexity, regulatory exclusivity, know-how, and government procurement position. A precise, current patent-expiration schedule is not established by the core public FDA approval materials alone.
For a monoclonal antibody such as obiltoxaximab, relevant protection can include:
- Composition-of-matter claims covering the antibody.
- Sequence claims covering variable regions or binding domains.
- Claims covering protective-antigen binding.
- Formulation and stability claims.
- Manufacturing-cell-line and production-process claims.
- Methods of treating or preventing anthrax infection.
- Regulatory exclusivity associated with the biologic approval.
The practical barrier to competition is likely higher than the patent barrier alone. A prospective biosimilar or follow-on competitor would need to establish analytical similarity, manufacturing consistency, clinical pharmacology, and regulatory acceptability for a product used in a rare and high-consequence indication.
Is there a generic or biosimilar launch risk for ANTHIM?
Near-term conventional generic risk is low because ANTHIM is a biologic monoclonal antibody administered intravenously. The relevant competitive pathway would be a biosimilar or interchangeable biologic, not a traditional small-molecule generic.
Commercial biosimilar risk is constrained by:
- Very small patient populations.
- A government-dominated customer base.
- High analytical and manufacturing costs.
- Limited recurring private-market demand.
- Need for validated production capacity.
- Potentially low return on investment absent a large stockpile contract.
- Government preference for reliable suppliers over multiple low-cost entrants.
A biosimilar could still become commercially relevant if it obtained a large federal procurement contract or if the government sought lower prices through competition. The principal threat would be procurement displacement rather than pharmacy substitution.
What generic launch scenarios exist for ANTHIM?
Three launch scenarios are commercially relevant.
No competing biologic
The incumbent retains most or all government procurement if it maintains regulatory compliance, manufacturing capacity, and competitive pricing. Revenue remains lumpy and dependent on replenishment orders.
Government-led dual sourcing
The government contracts with ANTHIM and a competing anthrax antitoxin. Total market volume may expand for preparedness reasons, but incumbent share and pricing may decline.
Biosimilar or follow-on entry
A competitor enters after developing a sufficiently similar antibody and securing government acceptance. Price pressure increases, but the entrant must still win procurement volume. FDA approval alone would not guarantee meaningful sales.
What are the main commercial risks?
ANTHIM’s largest commercial risk is customer concentration. A single federal buyer can account for most or all product demand. That concentration creates negotiating leverage for the government and exposes the supplier to changes in policy, budgets, and procurement timing.
Other risks include:
- Inventory expiration and replacement uncertainty.
- Manufacturing failure or batch rejection.
- Difficulty forecasting option exercises.
- Declining biodefense budgets.
- Procurement competition from ANTHRASIL.
- Limited private-sector demand.
- High fixed costs relative to annual production volume.
- Changes in the Strategic National Stockpile’s product mix.
- Ownership or licensing changes affecting supply continuity.
The company must preserve a specialized supply chain even during periods without visible demand. That creates a mismatch between readiness costs and revenue timing.
What is the long-term revenue outlook for ANTHIM?
The long-term outlook is best described as a low-volume, high-value, contract-dependent biodefense franchise.
The product can generate substantial revenue when the government funds stockpile expansion or replenishment. It cannot be modeled reliably as a standard recurring pharmaceutical franchise because revenue depends on discrete procurement events rather than prescription demand.
A practical forecasting framework is:
| Driver |
Effect on revenue |
| New stockpile procurement |
Sharp increase |
| Option exercise under existing contract |
Material increase |
| Inventory replacement |
Periodic increase |
| Product expiration |
Can support replenishment but does not guarantee it |
| Budget contraction |
Delayed or reduced orders |
| Competitor award |
Reduced share or pricing |
| Emergency event |
Potential acceleration, but unpredictable |
| Manufacturing disruption |
Revenue deferral and reputational risk |
The headline $1.25 billion contract ceiling indicates substantial theoretical opportunity, but it should not be used as a revenue forecast. The economically relevant measures are funded orders, delivered doses, realized unit price, manufacturing cost, and renewal probability.
Key Takeaways
- ANTHIM is a specialized anthrax antitoxin based on obiltoxaximab.
- The FDA approved it in March 2016 under the Animal Rule.
- Its market is dominated by U.S. government stockpile procurement.
- Elusys received a BARDA contract with a potential value of approximately $1.25 billion, but the ceiling was not guaranteed revenue.
- Initial procurement was publicly reported at roughly 60,000 doses and approximately $44 million.
- Public company disclosures do not provide a complete product-level revenue and profitability history.
- ANTHIM competes mainly with ANTHRASIL and other government-ready countermeasures.
- Conventional generic risk is low; biosimilar and procurement displacement risk are more relevant.
- Long-term revenue is likely to remain episodic, policy-sensitive, and dependent on stockpile replenishment.
- Manufacturing reliability, shelf life, government contracting, and regulatory compliance are more important than routine physician prescribing.
FAQs
Is ANTHIM sold through retail pharmacies?
No. ANTHIM is primarily a government-stockpiled emergency countermeasure rather than a retail pharmacy product.
Does ANTHIM generate recurring prescription revenue?
No. Its revenue model is based mainly on government procurement, stockpile replenishment, and emergency preparedness contracts.
Is ANTHIM interchangeable with ANTHRASIL?
No. Both are anthrax antitoxin monoclonal antibodies, but they are separate biologic products with distinct active ingredients and regulatory records.
Can a generic company copy ANTHIM?
A conventional generic pathway is not applicable. A competitor would generally need to develop and obtain approval for a biosimilar or another biologic anthrax antitoxin.
What is the most important financial metric for ANTHIM?
Funded government purchase orders and delivered doses are more informative than the aggregate contract ceiling. Contract options and ceilings do not equal recognized revenue.
References
- U.S. Food and Drug Administration. (2016). ANTHIM (obiltoxaximab) prescribing information.
- Biomedical Advanced Research and Development Authority. (2015). BARDA contract award for obiltoxaximab procurement for the Strategic National Stockpile. U.S. Department of Health and Human Services.
- U.S. Food and Drug Administration. (2016, March 18). FDA approves Anthim to treat inhalation anthrax and prevent inhalation anthrax following exposure.
- U.S. Food and Drug Administration. (2019). ANTHRASIL (raxibacumab) prescribing information.
